Needlefree Closed System Transfer Device (CSTD) Market Size, Share & Industry Analysis, By Type (Closed Vial Access Devices, Closed Syringe Safety Devices, and Closed Bag/Line Access Devices), By Application (Hospital and Clinic), Regional Insights and Forecast From 2025 To 2034

• 

  Request a Free sample to learn more about this report

NEEDLEFREE CLOSED SYSTEM TRANSFER DEVICE (CSTD) MARKET OVERVIEW

The global Needlefree Closed System Transfer Device (CSTD) Market size is projected to reach USD 0.552 billion in 2025, growing further to USD 2.303 billion by 2034 at an estimated CAGR of 19.54% from 2025 to 2034.

The United States Needlefree Closed System Transfer Device (CSTD) market size is projected at USD 0.177 billion in 2025, the Europe Needlefree Closed System Transfer Device (CSTD) market size is projected at USD 0.128 billion, and the China Needlefree Closed System Transfer Device (CSTD) market size is projected at USD 0.170 billion.

Needlefree Closed system transfer device (CSTD) is a medication device that precisely forbids the transfer of natural impurities into a system and the evasion of hazardous drug or fume concentrations outside the framework. Millions of healthcare workers are exposed to the toxic and hazardous drugs of chemotherapy and other medical treatments every year. Researches have shown that subjection to hazardous drugs can lead to serious health issues, such as reproductive system problems, cancer, and development problems. As per the Occupational Safety & Health Administration (OSHA), Joint Commission, and the National Institute of Occupational Safety & Health (NIOSH), the adverse effects can turn irreversible even on low exposure. The increasing prevalence of cancer amongst the ever-increasing population is anticipated to boost the market growth in the upcoming years.

KEY FINDINDS

COVID-19 IMPACT

Market to Witness Robust Growth Post-Pandemic

The humanitarian crisis has significantly impacted the global economic structure and stagnated the growth of several industries and markets. The needlefree closed system transfer device (CSTD) market has witnessed a limited impact of the COVID-19 pandemic. Due to the fear of contracting the virus at hospitals and clinics, the number of patients visiting hospitals and clinics declined. Cancer combined with the coronavirus can deteriorate the organs. This factor aggravated the situation and negatively impacted the market growth. However, the immense investments to bolster the healthcare sector has boosted the growth of the market. Moreover, the vaccines are now available to the masses, and nations around the globe have ramped up their vaccination drives. The market is anticipated to witness robust growth post-pandemic.

LATEST TRENDS

Increasing Investments to Fortify Healthcare Sector

The coronavirus pandemic has wreaked unprecedented chaos in the healthcare industry, and major economies’ healthcare infrastructures were on the verge of collapse during the pandemic. The lack of superior healthcare infrastructure has induced the governments of several nations to increase their investments in the healthcare sector. Additionally, the growing prevalence of cancer amongst the expanding global population has induced the governments of major economies to increase their research and development activities to developed advanced treatment methods and devices for cancer. The increasing government investments to fortify the healthcare sector are likely to foster the growth of the global needlefree closed system transfer device (CSTD) market.

• According to the World Health Organization’s (WHO) cancer control program data, over 16.2 million chemotherapy procedures were administered globally in 2023, leading to increased demand for CSTDs in infusion setups.

• As per the U.S. National Cancer Institute, more than 60% of oncology departments in federal hospitals integrated needlefree CSTDs into hazardous drug administration protocols between 2022 and 2024.

Request a Free sample to learn more about this report

NEEDLEFREE CLOSED SYSTEM TRANSFER DEVICE (CSTD) MARKET SEGMENTATION

By Type

the market bifurcates into closed bag/line access devices, closed syringe safety devices, and closed vial access devices.

Out of these, the closed vial access devices segment is anticipated to witness the highest growth in the market.

By Application

the market brifurcates into clinics and hospitals.

Geographically, the market is classified into five major regions- North America, Europe, Latin America, Asia Pacific, and the Middle East & Africa.

DRIVING FACTORS

Rising Prevalence of Cancer to Augment Market Growth

The global population has been expanding at exponential rates. The number of cancer cases has also increased with the ever-increasing population. The cancer patient pool caused by genes, viruses, or sedentary lifestyles has escalated in recent years. The sedentary lifestyle of consumers, such as excessive alcohol consumption, smoking, and tobacco consumption, increases the risk of getting cancer. It is expected that the number of cancer cases will approximately be about 29.5 million by 2040, and there will be approximately 16.4 million deaths by cancer. The increasing number of cancer cases are anticipated to surge the demand for needlefree closed system transfer device (CSTD) and augment the market growth.

Increasing Awareness for CSTD to Fuel Market Growth

The sedentary lifestyle habits of consumers, such as smoking and tobacco consumption, boost the chances of getting cancer and are likely to surge the growth of the needlefree closed system transfer device (CSTD) market. The increasing number of cancer cases and the growing awareness for needle-free transfer of medication drugs in chemotherapy is anticipated to fuel the demand for needlefree closed system transfer device (CSTD). Additionally, the increasing popularity and demand for non-invasive surgeries is expected to boost the needlefree closed system transfer device (CSTD) market growth. The growing expenditure by hospitals on the procurement of the advanced needlefree closed system transfer device (CTSD) is also estimated to drive the growth of the market.

• Based on the Global Cancer Observatory (GCO), the number of new cancer cases is projected to exceed 29.5 million by 2040, which directly increases the demand for safe drug handling technologies like CSTDs.

• According to NIOSH hazard reports, over 8 million healthcare workers in the U.S. are routinely exposed to hazardous drugs annually, creating urgent demand for closed drug-transfer systems in clinical settings.

RESTRAINING FACTORS

High Product Costs to Hamper Market Growth

The implementation costs of needlefree closed system transfer device (CSTD) is high and are mostly purchased by hospitals rather than clinics. The high costs incurred in the implementation of the product are anticipated to hinder the market growth. Moreover, the improper regulatory guidelines in underdeveloped and developing nations may also hamper the growth of the market.

• As reported by the U.S. Centers for Medicare & Medicaid Services, only 32.8% of small and medium-sized clinics in rural areas budgeted for CSTDs in 2023 due to high implementation costs.

• According to Africa CDC, more than 40% of low-income countries lack formal regulatory guidelines for the approval and integration of needlefree CSTDs in public healthcare settings.
• Request a Free sample to learn more about this report

•  

NEEDLEFREE CLOSED SYSTEM TRANSFER DEVICE (CSTD) MARKET REGIONAL INSIGHTS

Increasing Government Investments to Fortify Growth in Asia Pacific

Asia Pacific is anticipated to witness the highest growth in the global needlefree closes system transfer device (CSTD) market share. The increasing government investments to fortify the healthcare sector in countries such as India, China, and Japan, are anticipated to foster growth for the market. The rising need for advanced medical equipment in the region, coupled with the growing advancements in the medical sector, are expected to fuel the market growth. Additionally, the surging cancer research activities are likely to complement the growth of the needlefree closed system transfer device (CSTD) market.

North America is projected to gain the second-highest growth in the global market. The significant initiatives taken by the U.S. Food and Drug Administration and other regulatory institutions to ensure the safety of patients are anticipated to boost the market growth. The growing number of oncology drug approvals is likely to stimulate growth for the market. Additionally, the early adoption of technology and growing cancer research are estimated to surge the market growth.

Europe is expected to gain substantial growth in the upcoming years due to the increasing pool of cancer patients in the region. Additionally, the increasing investments to bolster the healthcare sector are anticipated to augment the market growth.

Latin America and the Middle East & Africa are estimated to witness considerable growth in the global market due to the expanding healthcare infrastructure in the two regions. The growing investments in the healthcare sector are likely to accumulate growth for the market. Additionally, the increasing focus of key players in the emerging markets is anticipated to foster the market growth in the upcoming years.

KEY INDUSTRY PLAYERS

Key Players Ramp Up R&D Activities to Launch Advanced Needlefree Closed System Transfer Device (CSTD)

The key players are conducting extensive research and development activities to develop advanced needlefree closed system transfer device (CSTD) which completely eliminate the risk of exposure to the hazardous drugs of chemotherapy. The key payers focus on organic growth strategies such as new product launches, technological developments, patents, etc., to increase the market presence. The key players also adopt inorganic growth strategies such as partnerships, mergers, acquisitions, collaborations, and others to enhance their market positions and generate greater revenues.

• BD Medical: BD Medical distributed over 1.1 million CSTDs globally in 2023, with the largest concentration in U.S. cancer centers and government-funded clinical research facilities.

• Equashield: Equashield’s patented CSTD technology was implemented in over 4,200 hospitals across North America and the Middle East by the end of 2024, supporting oncology drug compounding safety.

List of Top Needlefree Closed System Transfer Device (CSTD) Companies

• BD Medical
• Equashield
• ICU Medical
• Teva Medical
• Corvida Medical

KEY INDUSTRY DEVELOPMENTS

October 2018: Equashield LLC formed a strategic partnership with Max Care Hospital, Saudi Arabia to expand its CSTD distribution in the Middle East and Africa region.

REPORT COVERAGE

The global needlefree closed system transfer device (CSTD) market report offers a comprehensive assessment of the market and focuses on key factors, such as components, end-users, applications, and leading companies. Other than this, the report offers vital insights into the ongoing market trends and highlights key industry developments. In addition to the above-mentioned factors, the report envisages significant factors contributing to the market’s growth in recent years.